

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, C12P 19/34, C07H 21/04, G01N 33/00		A1	(11) International Publication Number: WO 99/13106
			(43) International Publication Date: 18 March 1999 (18.03.99)
(21) International Application Number: PCT/US98/18158 (22) International Filing Date: 2 September 1998 (02.09.98) (30) Priority Data: 60/058,612 10 September 1997 (10.09.97) US (71) Applicant: AXYS PHARMACEUTICALS, INC. [US/US]; 180 Kimball Way, South San Francisco, CA 94080 (US). (72) Inventors: LICHTER, Jay, B.; 5415 Caminito Exquisito, San Diego, CA 92130 (US). GUIDA, Marco; 1399 9th Avenue #1210, San Diego, CA 92101 (US). (74) Agent: SHERWOOD, Pamela, J.; Bozicevic, Field & Francis LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: GENOTYPING OF HUMAN CYP3A4			
(57) Abstract <p>Genetic polymorphisms are identified in the human CYP3A4 gene that alter CYP3A4-dependent drug metabolism. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for CYP3A4 substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and <i>in vitro</i> models for drug metabolism.</p>			

CA-Patent Application 2,381,066
Epidauros Biotechnologie AG
Your Ref.: 12976.36
Our Ref.: D2145 CA/2 S3

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

GENOTYPING OF HUMAN CYP3A4

INTRODUCTION

5 Cytochrome P450 enzymes are a heme-containing family that play central roles in oxidative, peroxidative and reductive metabolism of numerous endogenous and exogenous compounds, including many pharmaceutical agents. Substances known to be metabolized by P450 enzymes include steroids, bile acids, fatty acids, prostaglandins, leukotrienes, biogenic amines, retinoids, lipid hydroperoxides, phytoalexins, pharmaceuticals,
10 environmental chemicals and pollutants. P450 substrates also include natural plant products involved in flavor, odor, flower color, and the response to wounding. P450 enzymes and other drug-metabolizing enzymes maintain steady-state levels of endogenous ligands involved in ligand-modulated transcription of genes effecting growth, apoptosis, differentiation, cellular homeostasis, and neuroendocrine functions. The metabolism of
15 foreign chemicals by P450 enzymes can produce toxic metabolites, some of which have been implicated as agents responsible for birth defects and tumor initiation and progression.

 The P450 gene superfamily is likely to have evolved from an ancestral gene present before the prokaryote/eukaryote divergence. The number of individual P450 genes in any mammalian species is estimated at 60 to 200. The CYP2C and CYP3A subfamilies are
20 unique in that they are present in large amounts in human liver microsomes, and there are many forms in each subfamily. Several human cDNAs encoding CYP3A proteins have been identified. The most important of these are CYP3A4, CYP3A5 and CYP3A7. CYP3A4 and CYP3A7 genes are 87% homologous by amino acid and 95% homologous by nucleotide sequence, while CYP3A4 and CYP3A5 are only 88% homologous in the coding region.
25 CYP3A4 and CYP3A7 are 91% homologous in the 5'-flanking sequences, differing by the presence of a unique P450NF specific element (NFSE) and a P450HFLa specific element (HFLaSE), respectively (Hashimoto et al, 1993).

 It has been shown that polymorphisms in the CYP2D6 gene correlates with enzyme activity measured by phenotyping with dextromethorphan or debrisoquine (Sachse *et al.*
30 (1997) Am. J. Hum. Genet. 60:248-295).

 The CYP3A subclass catalyzes a remarkable number of oxidation reactions of clinically important drugs such as quinidine, warfarin, erythromycin, cyclosporin A, midazolam, lidocain, nifedipine, and dapsone. Current estimates are that more than 60% of clinically used drugs are metabolized by the CYP3A4 enzyme, including such major drug

classes as calcium channel blockers, immunosuppressors, macrolide antibiotics and anticancer drugs, see Brian *et al.* (1990) Biochemistry 29:11280-11292.

Expression profiles for each member of this family varies significantly. CYP3A4 is expressed in all adult human liver and intestine, accounting for more than 50% of total P450 in both organs. Expression is inducible *in vivo* and *in vitro* by numerous compounds such as rifampicin, barbiturates and glucocorticoids. In kidney, CYP3A4 is expressed polymorphically. CYP3A4 expression is sex-influenced, as females have 24% greater expression than males. CYP3A5 is detected in 10-30% of Caucasian adult livers, and expressed constitutively in adult kidney. CYP3A5 expression does not appear to be sex-influenced and only moderately inducible by xenobiotics both in vivo and in vitro. CYP3A7 is expressed in fetal liver but only in 25% of adult livers. Molecular mechanisms responsible for the developmentally specific expression of CYP3A's are unknown.

Since the rates of metabolism of drugs, toxins, *etc.* can depend on the amounts and kinds of P450s expressed in a tissue, variation in biological response may be determined by the profile of expression of P450s in each person. Analysis of genetic polymorphisms that lead to altered expression and enzyme activity are therefore of interest.

SUMMARY OF THE INVENTION

Genetic sequence polymorphisms are identified in the human CYP3A4 gene. Nucleic acids comprising the polymorphic sequences are used in screening assays, and for genotyping individuals. The genotyping information is used to predict the rate of metabolism for CYP3A4 substrates, and the effect that CYP3A4 modulators will have on such metabolism. The information allows better prediction of drug interactions, and effective dose for an individual.

DATABASE REFERENCES FOR NUCLEOTIDE SEQUENCES

Genbank accession no. S74700 provides the CYP3A5 5' genomic region. Genbank accession no. D11131 provides a partial sequence of the human cytochrome P-450IIIA4 gene. Genbank accession no. M18907 (cDNA) provides the cDNA sequence of a human CYP3A4 allele. Sequences of the CYP3A4 gene are provided in the SEQLIST as follows: cDNA sequence as SEQ ID NO:1, the encoded polypeptide as SEQ ID NO:2, the promoter region as SEQ ID NO:3, intron 3 as SEQ ID NO:4, intron 4 as SEQ ID NO:5, intron 6 as SEQ ID NO:6, exon 7, intron 7 as SEQ ID NO:7, intron 10 as SEQ ID NO:8, intron 11 as SEQ ID NO:9.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Pharmacogenetics is the linkage between an individual's genotype and that individual's ability to metabolize or react to a therapeutic agent. Differences in metabolism or target sensitivity can lead to severe toxicity or therapeutic failure by altering the relation
5 between bioactive dose and blood concentration of the drug. Relationships between polymorphisms in metabolic enzymes or drug targets and both response and toxicity can be used to optimize therapeutic dose administration.

Genetic polymorphisms are identified in the human CYP3A4 gene. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism
10 for CYP3A4 substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell culture and *in vitro* cell-free models for drug metabolism.

Definitions

15 It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

20 As used herein the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a construct" includes a plurality of such constructs and reference to "the CYP3A4 nucleic acid" includes reference to one or more nucleic acids and equivalents thereof known to those skilled in the art, and so forth. All technical and scientific terms used herein have the
25 same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs unless clearly indicated otherwise.

CYP3A4 polymorphic sequences. It has been found that specific sites in the CYP3A4 gene sequence are polymorphic, *i.e.* within a population, more than one nucleotide
30 (G, A, T, C) is found at a specific position. Polymorphisms may provide functional differences in the genetic sequence, through changes in the encoded polypeptide, changes in mRNA stability, binding of transcriptional and translation factors to the DNA or RNA, and the like. The polymorphisms are also used as single nucleotide polymorphisms (SNPs) to detect genetic linkage to phenotypic variation in activity and expression of the particular
35 protein.

SNPs are generally biallelic systems, that is, there are two alleles that an individual may have for any particular marker. SNPs, found approximately every kilobase, offer the potential for generating very high density genetic maps, which will be extremely useful for developing haplotyping systems for genes or regions of interest, and because of the nature of SNPs, they may in fact be the polymorphisms associated with the disease phenotypes under study. The low mutation rate of SNPs also makes them excellent markers for studying complex genetic traits.

In order to provide an unambiguous identification of the specific site of a polymorphism, sequences flanking the polymorphic site are shown in the tables, where the 5' and 3' flanking sequence is non-polymorphic, and the central position, shown in bold, is variable. It will be understood that there is no special significance to the length of non-polymorphic flanking sequence that is included, except to aid in positioning the polymorphism in the genomic sequence.

The sequence of at least one allele of human CYP3A4 is known in the art, and accessible in public databases, as cited above. This sequence is useful as a reference for the genomic location of the human gene, and for specific coding region sequences. The subject polymorphic sequences are provided in Table 3, and include the CYP3A4-A392/CYP3A4-G392 alternative forms, which are associated with differences in expression level of the polypeptide. As used herein, the term "CYP3A4 gene" is intended to refer to both the wild-type and variant sequences, unless specifically denoted otherwise.

Nucleic acids of particular interest comprise the provided variant nucleotide sequence(s). For screening purposes, hybridization probes may be used where both polymorphic forms are present, either in separate reactions, or labeled such that they can be distinguished from each other. Assays may utilize nucleic acids that hybridize to one or more of the described polymorphisms.

The genomic CYP3A4 sequence, including specific transcriptional and translational regulatory sequences, such as promoters, enhancers, *etc.*, including about 1 kb, but possibly more, of flanking genomic DNA at the 5' end of the transcribed region, is of particular interest. The promoter region is useful for determining the pattern of CYP3A4 expression, *e.g.* induction and inhibition of expression in various tissues, and for providing promoters that mimic these native patterns of expression. A polymorphic CYP3A4 gene sequence, *i.e.* including one or more of the provided polymorphisms, is useful for expression studies to determine the effect of promoter and/or intron sequence variations on mRNA expression and stability. The polymorphisms are also used as single nucleotide

polymorphisms to detect genetic linkage to phenotypic variation in activity and expression of CYP3A4.

As used herein, the term ACYP3A4 gene@ is intended to generically refer to both the wild-type (reference) and variant forms of the sequence, unless specifically denoted otherwise. As it is commonly used in the art, the term Agene@ is intended to refer to the genomic region encompassing the 5' UTR, exons, introns, and the 3' UTR. Individual segments may be specifically referred to, *e.g.* exon 2, intron 5, *etc.* Combinations of such segments that provide for a complete protein may be referred to generically as a protein coding sequence.

The promoter region of CYP3A4 contains a number of sequence motifs for binding transcription regulatory factors. These include a basic transcription element (SEQ ID NO:1, nt. 1054-1071); octamer motif (SEQ ID NO:1, nt. 975-982); TATA box (SEQ ID NO:1, nt. 1075-1081); HNF-5 site (SEQ ID NO:1, nt. 913-920); estrogen responsive elements (SEQ ID NO:1, nt. 735-750, 895-908); CAAT box (SEQ ID NO:1, nt. 843-848); p53 binding site (SEQ ID NO:1, nt. 721-735); AP-3 binding site (SEQ ID NO:1, nt. 682-693); NFSE site (SEQ ID NO:1, nt. 810-819); and progesterone/glucocorticoid responsive element (SEQ ID NO:1, nt. 870-883). Regulatory sequences can be used to identify trans acting factors that regulate or mediate CYP3A4 expression.

Fragments of the DNA sequence are obtained by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, *etc.* For the most part, DNA fragments will be of at least 15 nt, usually at least 20 nt, often at least 50 nt. Such small DNA fragments are useful as primers for PCR, hybridization screening, *etc.* Larger DNA fragments, *i.e.* greater than 100 nt are useful for production of the encoded polypeptide, promoter motifs, *etc.* For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of primer sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art.

The CYP3A4 nucleic acid sequences are isolated and obtained in substantial purity, generally as other than an intact mammalian chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include a CYP3A4 sequence or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

CYP3A4 polypeptides. The CYP3A4 genetic sequence, including polymorphisms, may be employed for synthesis of a complete CYP3A4 protein, or polypeptide fragments thereof, particularly fragments corresponding to functional domains; binding sites; etc.; and including fusions of the subject polypeptides to other proteins or parts thereof. For
5 expression, an expression cassette may be employed, providing for a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region. Various transcriptional initiation regions may be employed that are functional in the expression host. The polypeptides may
10 be expressed in prokaryotes or eukaryotes in accordance with conventional ways, depending upon the purpose for expression. Small peptides can also be synthesized in the laboratory.

Substrate: a chemical entity that is modified by CYP3A4 oxidation, usually under
15 normal physiological conditions. Most of these substrates are lipophilic compounds. Although the duration of drug action tends to be shortened by metabolic transformation, drug metabolism is not "detoxification". Frequently the metabolic product has greater biologic activity than the drug itself. In some cases the desirable pharmacologic actions are entirely attributable to metabolites, the administered drugs themselves being inert. Likewise,
20 the toxic side effects of some drugs may be due in whole or in part to metabolic products.

The range of known substrates for CYP3A4 is very broad, including steroids, e.g. testosterone, estradiol, mifepristone; tricyclic antidepressants, e.g. amitriptyline, clomipramine, imipramine, desipramine; SSRI, e.g. citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline; bile acids; protease inhibitors, e.g. saquinovir, indinavir; fatty acids;
25 prostaglandins; leukotrienes; biogenic amines; retinoids; lipid hydroperoxides; phytoalexins; antibiotics, e.g. erythromycin; taxanes, e.g. paclitaxel, docetaxel; anti-hypertensives, e.g. diltiazem; environmental chemicals and pollutants, felodipine, rifabutin, haloperidol, triazolam, terfenadine, lovastatin, chlorzoxazone, alprazolam, etc.

Modifier. A chemical agent that modulates the action of CYP3A4, either through
30 altering its enzymatic activity (enzymatic modifier) or through modulation of expression (expression modifier). In some cases the modifier may also be a substrate, thereby inducing its own demise. Selective inhibitors of CYP3A4 include ketoconazole and troleandomycin. Other P450 selective inhibitors include venlafaxine, clarithromycin, fluconazole, itraconazole,
35 ritonavir, orphenadrine, methimazole, midazolam, gestodene, etc. Recent studies have

shown that orally administered grapefruit juice is an expression modifier of CYP3A4, acting to specifically down-regulate expression in enterocytes (Lown *et al.* (1997) J. Clin. Invest 99:2545-2553).

Recent studies (Schuetz and Schuetz (1996) Mol Pharmacol 49:311-318) on
5 expression of P-glycoprotein and CYP3A4 showed that both proteins were up-regulated after treatment with many drugs, including rifampicin, phenobarbital, clotrimazole, reserpine, and isosafrole. P-glycoprotein was up-regulated by midazolam and nifedipine, whereas CYP3A4 was not. Azoles appear to be broad spectrum inhibitors of cytochromes P450.

10 *Pharmacokinetic parameters.* Pharmacokinetic parameters provide fundamental data for designing safe and effective dosage regimens. A drug's volume of distribution, clearance, and the derived parameter, half-life, are particularly important, as they determine the degree of fluctuation between a maximum and minimum plasma concentration during a dosage interval, the magnitude of steady state concentration and the time to reach steady
15 state plasma concentration upon chronic dosing. The pharmacokinetics of drugs often vary considerably between individuals, largely because of variations in the expression of CYP enzymes in the liver and other tissues. Parameters derived from *in vivo* drug administration are useful in determining the clinical effect of a particular CYP3A4 genotype.

20 *Expression assay.* An assay to determine the effect of a sequence polymorphism on CYP3A4 expression. Expression assays may be performed in cell-free extracts, or by transforming cells with a suitable vector. Alterations in expression may occur in the basal level that is expressed in one or more cell types, or in the effect that an expression modifier has on the ability of the gene to be inhibited or induced. Expression levels of a variant
25 alleles are compared by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as β -galactosidase, luciferase, chloramphenicol acetyltransferase, *etc.* that provides for convenient quantitation; and the like. Specific constructs for determining promoter strength
30 of CYP3A4 are described in Hashimoto *et al.* (1993) Eur. J. Biochem. 218:585-595.

Gel shift or electrophoretic mobility shift assay provides a simple and rapid method for detecting DNA-binding proteins (Ausubel, F.M. *et al.* (1989) In: Current Protocols in Molecular Biology, Vol. 2, John Wiley and Sons, New York). This method has been used widely in the study of sequence-specific DNA-binding proteins, such as transcription factors.
35 The assay is based on the observation that complexes of protein and DNA migrate through

a nondenaturing polyacrylamide gel more slowly than free DNA fragments or double-stranded oligonucleotides. The gel shift assay is performed by incubating a purified protein, or a complex mixture of proteins (such as nuclear or cell extract preparations), with an end-labeled DNA fragment containing the putative protein binding site. The reaction products are then analyzed on a nondenaturing polyacrylamide gel. The specificity of the DNA-binding protein for the putative binding site is established by competition experiments using DNA fragments or oligonucleotides containing a binding site for the protein of interest, or other unrelated DNA sequences.

CYP3A4 is known to be expressed in liver, e.g. embryonic liver, mature hepatocytes; duodenal tissue, e.g. mucosal epithelial cells; and other epithelial cells throughout the digestive tract; breast tissue; placental tissue; lung tissue, e.g. bronchial glands, bronchiolar columnar and terminal epithelium, type II alveolar epithelium and alveolar macrophages, etc. Hepatic levels of CYP3A4 can be estimated by an erythromycin breath test, and vary by at least 10-fold among patients.

Substrate screening assay. Assays to determine the metabolic activity of a CYP3A4 protein or peptide fragment on a substrate. Many suitable assays are known in the art, including the use of primary or cultured cells, e.g. epithelial cells from liver, intestine, etc., genetically modified cells where the native CYP3A4 alleles are altered or inactivated, cell-free systems, e.g. microsomal preparations or recombinantly produced enzymes in a suitable buffer, or in animals, including human clinical trials. Clinical trials may monitor serum, urine, etc. levels of the substrate or its metabolite(s).

Typically a candidate substrate is input into the assay system, and the oxidation to a metabolite is measured over time. The choice of detection system is determined by the substrate and the specific assay parameters. Assays are conventionally run, and will include negative and positive controls, varying concentrations of substrate and enzyme, etc.

Genotyping: CYP3A4 genotyping is performed by DNA or RNA sequence and/or hybridization analysis of any convenient sample from a patient, e.g. biopsy material, blood sample, scrapings from cheek, etc. A nucleic acid sample from an individual is analyzed for the presence of polymorphisms in CYP3A4, particularly those that affect the activity or expression of CYP3A4. Specific sequences of interest include any polymorphism that leads to changes in basal expression in one or more tissues, to changes in the modulation of CYP3A4 expression by modifiers, or alterations in CYP3A4 substrate specificity and/or activity.

Linkage Analysis: Diagnostic screening may be performed for polymorphisms that are genetically linked to a phenotypic variant in CYP3A4 activity or expression, particularly through the use of microsatellite markers or single nucleotide polymorphisms (SNP). The microsatellite or SNP polymorphism itself may not phenotypically expressed, but is linked to sequences that result in altered activity or expression. Two polymorphic variants may be in linkage disequilibrium, *i.e.* where alleles show non-random associations between genes even though individual loci are in Hardy-Weinberg equilibrium.

Linkage analysis may be performed alone, or in combination with direct detection of phenotypically evident polymorphisms. The use of microsatellite markers for genotyping is well documented. For examples, see Mansfield *et al.* (1994) Genomics 24:225-233; and Ziegler *et al.* (1992) Genomics 14:1026-1031. The use of SNPs for genotyping is illustrated in Golevleva *et al.* (1996) Am. J. Hum. Genet. 59:570-578; and in Underhill *et al.* (1996) P.N.A.S. 93:196-200.

Transgenic animal. The subject nucleic acids can be used to generate genetically modified non-human animals or site specific gene modifications in cell lines. The term "transgenic" is intended to encompass genetically modified animals having a deletion or other knock-out of CYP3A4 gene activity, having an exogenous CYP3A4 gene that is stably transmitted in the host cells, or having an exogenous CYP3A4 promoter operably linked to a reporter gene. Transgenic animals may be made through homologous recombination, where the CYP3A4 locus is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like. Of interest are transgenic mammals, *e.g.* cows, pigs, goats, horses, *etc.*, and particularly rodents, *e.g.* rats, mice, *etc.*

Genetically Modified Cells. Primary or cloned cells and cell lines are modified by the introduction of vectors comprising CYP3A4 gene polymorphisms. The gene may comprise one or more variant sequences, preferably a haplotype of commonly occurring combinations. U.S. 5,429,948, July 4, 1995 describes the construction and use of a cell line that expresses multiple P450 enzymes.

Vectors useful for introduction of the gene include plasmids and viral vectors, *e.g.* retroviral-based vectors, adenovirus vectors, *etc.* that are maintained transiently or stably in mammalian cells. A wide variety of vectors can be employed for transfection and/or integration of the gene into the genome of the cells. Alternatively, micro-injection may be employed, fusion, or the like for introduction of genes into a suitable host cell.

The expression vector will have a transcriptional initiation region oriented to produce functional mRNA, preferably the native transcriptional initiation region, e.g. including the polymorphism described in Table 3. Generally the vectors will include markers for selection, and may also comprise detectable markers operably linked to the CYP3A4 promoter,
5 transcription cassettes for internal controls, etc.

Cell-free assay systems. A number of cell-free assays have been described that are useful in the subject invention. Yamazaki et al. (1997) Arch Biochem Biophys 342:329-337 demonstrates reconstituted systems with recombinantly produced CYP3A4. U.S. 5,413,915
10 describes microsomal P-450 oxidase enzyme complex dispersed in a thin film of a generally neutral hydrophilic film-forming binder. Substrates are converted into metabolic intermediates that can be detected by a colorimetric indicator present in the binder film or an adjacent binder film and undergoing a visible color change. U.S. 5,478,723 discloses methods for determining the enzyme or enzymes in the human body that metabolize a
15 particular drug by comparing microsomal fractions from different donors.

Genotyping Methods

The effect of a polymorphism in CYP3A4 gene sequence on the response to a particular substrate or modifier of CYP3A4 is determined by *in vitro* or *in vivo* assays. Such
20 assays may include monitoring the metabolism of a substrate during clinical trials to determine the CYP3A4 enzymatic activity, specificity or expression level. Generally, *in vitro* assays are useful in determining the direct effect of a particular polymorphism, while clinical studies will also detect an enzyme phenotype that is genetically linked to a polymorphism.

The response of an individual to the substrate or modifier can then be predicted by
25 determining the CYP3A4 genotype, with respect to the polymorphism. Where there is a differential distribution of a polymorphism by racial background, guidelines for drug administration can be generally tailored to a particular ethnic group.

The polymorphisms in the sequence of CYP3A4 provided in Table 3, particularly the A to G substitution at -392, are screened for the effect of the polymorphism on expression.
30 Several effects are of interest, including basal expression levels in different tissues, alterations in enzyme activity or specificity, and the induction or inhibition of expression by modifiers. The latter is of particular interest in determining drug-drug interactions. In particular, pharmacokinetic drug interactions with antimicrobials are common because of the tendency to prescribe them in combination with other therapies.

Tissue specific differences in expression are of interest because the metabolism of drugs can vary with the route of administration. For example, certain orally administered drugs are affected by the CYP3A4 expression level in enterocytes, while the same drug administered intravenously is only affected by hepatic expression levels of CYP3A4.

5 The basal expression level in different tissue may be determined by analysis of tissue samples from individuals typed for the presence or absence of a specific polymorphism. For example, the CYP3A4 mRNA or protein level in hepatocytes, gastrointestinal epithelial, *etc.* is determined. Any convenient method may be use, *e.g.* ELISA, RIA, *etc.* for protein quantitation, northern blot or other hybridization analysis, quantitative RT-PCR, *etc.* for
10 mRNA quantitation. The tissue specific expression is correlated with the genotype.

Alternatively, basal expression levels are determined by expression assays for the particular promoter sequence, as previously described. The assays may be performed with the CYP3A4 coding sequence or with a detectable marker sequence. To determine tissue specificity the assay is performed in cells derived from different sources.

15 The alteration of CYP3A4 expression in response to a modifier is determined by administering or combining the candidate modifier with an expression system, *e.g.* animal, cell, *in vitro* transcription assay, *etc.* The effect of the modifier on CYP3A4 transcription and/or steady state mRNA levels is determined. As with the basal expression levels, tissue specific interactions are of interest. Correlations are made between the ability of an
20 expression modifier to affect CYP3A4 activity, and the presence of the provided polymorphisms. A panel of different modifiers, cell types, *etc.* may be screened in order to determine the effect under a number of different conditions.

A CYP3A4 polymorphism that results in altered enzyme activity or specificity is determined by a variety of assays known in the art. The enzyme may be tested for
25 metabolism of a substrate *in vitro*, for example in defined buffer, or in cell or subcellular lysates, where the ability of a substrate to be oxidized by CYP3A4 under physiologic conditions is determined. Where there are not significant issues of toxicity from the substrate or metabolite(s), *in vivo* human trials may be utilized, as previously described.

The genotype of an individual is determined with respect to the provided CYP3A4
30 gene polymorphisms. The genotype is useful for determining the presence of a phenotypically evident polymorphism, and for determining the linkage of a polymorphism to phenotypic change.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence. Where large amounts of DNA are available, genomic DNA is used
35 directly. Alternatively, the region of interest is cloned into a suitable vector and grown in

- sufficient quantity for analysis. The nucleic acid may be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. The use of the polymerase chain reaction is described in Saiki *et al.* (1985) Science 239:487, and a review of current techniques may be found in Sambrook *et al.*
- 5 Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp.14.2–14.33. Amplification may be used to determine whether a polymorphism is present, by using a primer that is specific for the polymorphism. Alternatively, various methods are known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, for examples see Riley *et al.* (1990) N.A.R. 18:2887-2890; and Delahunty *et al.* (1996) Am. J. Hum.
- 10 Genet. 58:1239-1246.

A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4',7'-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, e.g. 32P, 35S, 3H; etc. The label may be

15 a two stage system, where the amplified DNA is conjugated to biotin, haptens, etc. having a high affinity binding partner, e.g. avidin, specific antibodies, etc., where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the

20 primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

The sample nucleic acid, e.g. amplified or cloned fragment, is analyzed by one of a number of methods known in the art. The nucleic acid may be sequenced by dideoxy or other methods. Hybridization with the variant sequence may also be used to determine its

25 presence, by Southern blots, dot blots, etc. The hybridization pattern of a control and variant sequence to an array of oligonucleotide probes immobilised on a solid support, as described in U.S. 5,445,934, or in WO95/35505, may also be used as a means of detecting the presence of variant sequences. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), mismatch cleavage detection,

30 and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease (restriction fragment length polymorphism, RFLP), the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was

digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

In one embodiment of the invention, an array of oligonucleotides are provided, where discrete positions on the array are complementary to one or more of the provided polymorphic sequences, e.g. oligonucleotides of at least 12 nt, frequently 20 nt, or larger, and including the sequence flanking the polymorphic position. Such an array may comprise a series of oligonucleotides, each of which can specifically hybridize to a different polymorphism. For examples of arrays, see Hacia *et al.* (1996) Nature Genetics 14:441-447; Lockhart *et al.* (1996) Nature Biotechnol. 14:1675-1680; and De Risi *et al.* (1996) Nature Genetics 14:457-460.

The genotype information is used to predict the response of the individual to a particular CYP3A4 substrate or modifier. Where an expression modifier, e.g. a macrolide drug, inhibits CYP3A4 expression, then drugs that are a CYP3A4 substrate will be metabolized more slowly if the modifier is co-administered. Where an expression modifier induces CYP3A4 expression, a co-administered substrate will typically be metabolized more rapidly. Similarly, changes in CYP3A4 activity will affect the metabolism of an administered drug. The pharmacokinetic effect of the interaction will depend on the metabolite that is produced, e.g. a prodrug is metabolized to an active form, a drug is metabolized to an inactive form, an environmental compound is metabolized to a toxin, etc. Consideration is given to the route of administration, drug-drug interactions, drug dosage, etc.

The CYP3A4-A392/CYP3A4-G392 alternative forms are shown to be differentially distributed between broadly defined racial groups. The G form is more prevalent in African Americans, while the A form is more prevalent in American Caucasians and American Hispanics. The administration of CYP3A4 substrates and expression modifiers may be adjusted to reflect racial differences in metabolism.

EXPERIMENTAL

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention, and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (e.g. amounts, temperature, concentrations, etc.) but some experimental errors and deviations should be allowed for. Unless otherwise indicated, parts are parts by weight, molecular weight is

average molecular weight, temperature is in degrees centigrade; and pressure is at or near atmospheric.

MATERIALS AND METHODS

5 *DNA samples.* Blood specimens from approximately 300 individuals were collected after obtaining informed consent. All samples were stripped of personal identifiers to maintain confidentiality. The only data associated with a given blood sample was gender and self-reported major racial group designations in the United States (Caucasian, Hispanic, African American). Genomic DNA was isolated from these samples using standard
10 techniques. gDNA was either stored as concentrated solutions or stored dried in microtiter plates for future use.

PCR amplifications. The primers used to amplify exons 5, 6, 7, 10, 12, and the promoter region of the CYP3A4 gene from 200 ng of human gDNA are shown in Table 1. Primers were designed based upon publically available cDNA and intron/exon boundary
15 sequence, as well as intron sequences determined in our laboratory. 100 ng of gDNA from 2 individuals was amplified with the Perkin Elmer GeneAmp PCR kit according to manufacturer's instructions in 100 μ l reactions with Taq Gold DNA polymerase, with one exception. Boehringer-Mannheim Expand High Fidelity PCR System kit was used to amplify intron 3. Magnesium concentrations for each PCR reaction was optimized empirically, and
20 are shown in Table 1. Thermal cycling was performed in a GeneAmp PCR System 9600 PCR machine (Perkin Elmer) with an initial denaturation step at 95°C for 10 min, followed by 35 cycles of denaturation at 95°C for 30 sec, primer annealing at 55°C for 45 sec, and primer extension at 72°C for 2 min, followed by final extension at 72°C for 5 min, with the following exceptions. Annealing temperature for the promoter fragment was 58°C. Cycling
25 conditions for intron 3 were an initial denaturation at 95°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 sec, primer annealing at 55°C for 45 sec, and primer extension at 68°C for 6 min, followed by a final extension at 68°C for 7 min.

DNA sequencing. PCR products from 32 individuals, approximately 1/3 representing each of the 3 major racial groups (see above), were spin column purified using
30 Microcon-100 columns. Cycle sequencing was performed on the GeneAmp PCR System 9600 PCR machine (Perkin Elmer) using the ABI Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit according to the manufacturer's directions. Oligonucleotide primers used for the sequencing reactions are listed in Table 2. 8 μ l sequencing reactions were subjected to 30 cycles at 96°C for 20 sec, 50°C for 20 sec, and 60°C for 4 min,
35 followed by ethanol precipitation. Samples were evaporated to dryness at 50°C for ~15 min

and resuspended in 2 μ l of loading buffer (5:1 deionized formamide : 50 mM EDTA pH 8.0), heated to 65°C for 5 min, and electrophoresed through 4% polyacrylamide/6M urea gels in an ABI 377 Nucleic Acid Analyzer according to the manufacturer's instructions for sequence determination. All sequences were determined from both the 5' and 3' (sense and antisense) direction.

Each sequencing reaction was performed with 2 individuals' DNA pooled together. The 16 electropherograms were analyzed by comparing peak heights, looking for ~25% reduction in peak size and/or presence of extra peaks as an indication of heterozygosity. Each electropherogram result that suggested the presence of a polymorphism was confirmed by individually resequencing each of the individuals' belonging to that pool on both strands.

Population genotyping. High-throughput genotyping using TaqMan technology (ABI) was performed using standard techniques (Livak *et al.* (1995) PCR Methods and Applications 4:357-362) on the samples described above. The promoter region from -422 to -331 was amplified using oligonucleotide primers CYP3A4_Promo1A (SEQ ID NO:10) (5'-TGGCTTGTTGGGATGAATTTCAAG-3') and CYP3A4_Promo1B (SEQ ID NO:11) (5'-TTACTGGGGAGTCCAAGGGTTCTG-3') at a concentration of 1.0 mM in 25 μ l reactions containing 7.5 mM MgCl₂. CYP3A4_APromo1, Fam-labeled (SEQ ID NO:12) (5'-TTAAATCGCCTCTCTCTTGCCCTTGTCTCTAT-3') and CYP3A4_GPromo1, Tet-labeled (SEQ ID NO:13) (5'-AATCGCCTCTCTCTGCGCCTTGTCTCTAT-3') oligonucleotide probes at a concentration of 100 nM were incorporated into the reactions for polymorphism detection. Thermal cycling was performed in a GeneAmp PCR System 9600 PCR machine (Perkin Elmer) with an initial incubation at 50°C for 2 min, followed by an initial denaturation step at 95°C for 10 min, followed by 45 cycles of denaturation at 95°C for 30 sec and primer annealing/extension at 66°C for 1 min. Results were automatically read on an LS50B (Perkin-Elmer).

RESULTS

A 664 bp fragment of the human CYP3A4 gene, which included 470 bp of the promoter region and 174 bp of exon 1, and 20 bp of intron 1 was amplified and resequenced. An adenine (A) to guanine (G) transition was identified at position -392 (from the start codon) which occurred at a frequency of approximately 30% in the racially-mixed 64 chromosomes screened by resequencing. Subsequent genotyping of 95 individuals from each of 3 broadly defined racial groups (African Americans, Hispanic Americans, and Caucasian Americans) produced the following allele frequencies:

Group	CYP3A4-A392	CYP3A4-G392
American Caucasians	.963	.037
American Hispanics	.931	.069
African Americans	.473	.527

5

A cytosine (C) to thymine (T) change was identified at position +52 of intron 6 which occurred at a frequency of approximately 1% in the racially-mixed 64 chromosomes screened by resequencing. A T to G change was identified at position +34 of intron 7 which occurred at a frequency of approximately 19% in the racially-mixed 64 chromosomes screened by resequencing. A silent mutation C to T was identified at position 579 of exon 7 that occurred at a frequency of approximately 3% in the racially-mixed 64 chromosomes screened by resequencing. A G to C change was identified at position -9 of intron 4 which occurred at a frequency of approximately 1.5% in the racially-mixed 64 chromosomes screened by resequencing. A G to A change was identified at position +12 of intron 10 which occurred at a frequency of approximately 14% in the racially-mixed 64 chromosomes screened by resequencing. A C to T change was identified at position -11 of intron 11 which occurred at a frequency of approximately 12% in the racially-mixed 64 chromosomes screened by resequencing. A dinucleotide microsatellite sequence, (CA)₁₆ was identified approximately 500 bp into intron 3 in a single person. Table 3 contains a summary of all the polymorphisms identified.

A 664 bp fragment of the 5' region of CYP3A4 gene was sequenced in 64 chromosomes representative of three major ethnic groups. The 470 bp of the promoter region amplified contains the TATA, the CAAT boxes and the octamer motif, as well as major regulatory elements such as the basic-transcription element, the NFSE, the p53 binding motif, the AP-3 binding site, a progesterone-glucocorticoid and two estrogen response elements, and a hepatic nuclear factor-5 response element. The polymorphism at position -392 lies in the 7th position of the 10 bp NFSE. Evidence from previous studies suggest that the NFSE is part of the regulatory region for CYP3A4 transcription (Hashimoto *et al.* (1993) *Eur J Biochem* 218:585-595).

The A to G change nucleotide change observed in the CYP3A4 NFSE at position 7 produces the sequence found in the CYP3A5 NFSE at position 7. Because the NFSE may partially account for differential expression of CYP3A4 and CYP3A5, this change in CYP3A4

could alter levels of expression and/or tissue specificity, perhaps making it more similar to the expression pattern of CYP3A5.

Allelic frequencies for the -392 polymorphism vary dramatically among the three populations tested. Several hypotheses may explain this phenomenon. This result may be due to genetic drift in the Caucasian and Hispanic populations that has severely restricted transmission, by chance alone, of the most frequent allele in African Americans. A shift in frequency of this magnitude seems unlikely for a locus in large human populations to experience simply by chance. Alternatively, a founder effect could account for this result, but this is also extremely unlikely for large, outbred populations collected without phenotypic selection or ascertainment bias. Another possibility is that natural selection has acted upon this locus, to perhaps restrict the G allele in modern Caucasian and Hispanic populations that originally arose from an African founder population (Cavalli-Sforza et al. The history and Geography of human genes. Princeton: Princeton University Press, 1994) in which the G allele was very common. Alternatively, the G allele may provide a selective advantage in the African environment, so that it has been maintained at a high frequency in the African American population that has only recently migrated from Africa. This hypothesis directly implies that this polymorphism affects CYP3A4 expression, and may be important in modulating metabolism of xenobiotic and pharmaceutical agents.

The (CA)_n repeat in intron 3 is very useful, as polymorphisms of this type usually are highly polymorphic in human populations with many alleles represented. This polymorphism is therefore useful in genetic transmission studies and provides a genetic "handle" for larger numbers of CYP3A4 gene haplotypes. The alterations identified at positions -9 and -11 of introns 4 and 11 respectively may vary the efficiency of mRNA post transcriptional processing because of their proximity to the intron/exon boundaries.

Table 1. PCR primers and Mg⁺⁺ concentrations.

SEQ	Region		[Mg ⁺⁺]
14	Promoter	TGAGGAGTTTGGTGAGG	2mM
15		CAAGAAACAGAGAAGAGG	
16	Exon 5	CCCACACAAATACATCC	2mM
17		AGAAGACATGGCTTTCC	
18	Exon 6	TGTCACTTACTGCTCCA	1mM
19		CAACAGGAAACCCACA	
20	Exon 7	TCCACAATCAATACATGC	2.5mM
21		CCTGAAGCCAGCAGA	
22	Exon 12	CATCTCAACAAGACTGAAAG	1.1mM
23		TGAACTCCAGAACTGAAG	
24	Intron 3	GGCTTTTGTATGTTTGAC	1mM
25		CGGTTTGTGAAGACAG	
26	Intron 10	CCTTGGGGAAACTGGAT	1.5mM
27		CTCCTGGGAAGTGGTG	

Table 2. Sequencing primers.

	Region	Forward Primer	
28	Promoter(1)	TGAGGAGTTTGGTGAGG	
29		CAAGAAACAGAGAAGAGG	
30	Promoter(2)	GTGAGTGGTGTGTGTGTG	
31		GTGATTCAGTGAGGCTGT	
32	Exon 5	GGGATAAATCTCTATTGAGCA	
33		GCTTTCCTCAGCATGGA	
34	Exon 6	TGTCACTTACTGCTCCA	
35		CACAGGGGAGAAGATCC	
36	Exon 7	TGTCTGTCTGGACTGGAC	
37		AAAATGATGATGGTCACAC	
38	Exon 12	TAGTGTGAGGAGAGTAGAAAG	
39		GCCTAATTGATTCTTTGG	
40	Exon 10	ATTGTCCTTATTCTGGTT	
41		CTCCTGGGAAGTGGTG	
42	Intron 3	GGCTTTTGTATGTTTGAC	

Table 3. CYP3A4 gene polymorphisms.

SEQ	Location	Polymorphisms	Position	SEQ ID NO
	Promoter	A to G	-392	SEQ ID NO:1, nt 816
43	ACAAGGGCAAGAGAGAGGC			
44	ACAAGGGCAGGAGAGAGGC			
	Intron 3	CA repeat	+506	SEQ ID NO:2, nt 560-591
45	GGGTTTTTA			
46	GGGTTTTTACACACACACACACACACACACACACACACA			
	Intron 4	G to C	-9	SEQ ID NO:3, nt 114
47	TTCTGCTTTGAACTCTAGC			
48	TTCTGCTTTCAACTCTAGC			
	Intron 6	T to G	+52	SEQ ID NO:4, nt 183
49	CCCTCCAGCTGCCTGCCAT			
50	CCCTCCAGCGGCCTGCCAT			
	Exon 7	C to T	579	SEQ ID NO:5, nt 88
51	AGTGAACATCGACTCTCTC			
52	AGTGAACATTGACTCTCTC			
	Intron 7	T to G	+34	SEQ ID NO:5, nt 213
53	ATTTATCTTTCTCTCTTAA			
54	ATTTATCTTGCTCTCTTAA			
	Intron 10	G to A	+12	SEQ ID NO:6, nt 293
55	GAGTGGATGGTACATGGAG			
56	GAGTGGATGATACATGGAG			
	Intron 11	C to T	-11	SEQ ID NO:7, nt 235
57	TCTACCAACGTGGAACCA			
58	TCTACCAATGTGGAACCA			

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit
5 or scope of the appended claims.

What is Claimed is:

1. An isolated nucleic acid molecule comprising a CYP3A4 sequence polymorphism, as part of other than a naturally occurring chromosome.
- 5 2. The isolated nucleic acid of Claim 1, wherein said nucleic acid comprises the nucleotide sequence as set forth in SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO: 48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, or SEQ ID NO:58.
3. The isolated nucleic acid of Claim 1, wherein said nucleic acid is a
10 hybridization probe of at least 18 nucleotides in length.
4. The isolated nucleic acid of Claim 3, wherein said probe is conjugated to a detectable marker.
- 15 5. An array of oligonucleotides comprising:
at least one probe of Claim 3 for detection of CYP3A4 locus polymorphisms.
6. A method for detecting in an individual a polymorphism in CYP3A4 metabolism of a substrate, the method comprising:
20 analyzing the genome of said individual for the presence of at least one CYP3A4 polymorphism listed in Table 3; wherein the presence of said predisposing polymorphism is indicative of an alteration in CYP3A4 expression or activity.
7. The method of Claim 6, wherein said analyzing step comprises detection of
25 specific binding between the genomic DNA of said individual with a probe according to Claim 3.
8. The method of Claim 6, wherein said analyzing step comprises detection of specific binding between the genomic DNA of said individual with an array according to
30 Claim 5.
9. The method of Claim 6, wherein said alteration in CYP3A4 expression is tissue specific.

10. The method of Claim 6, wherein said alteration in CYP3A4 expression is in response to a CYP3A4 modifier.

11. The method of Claim 10, wherein said modifier induces CYP3A4 expression.

5

12. The method of Claim 10, wherein said modifier inhibits CYP3A4 expression.

SEQUENCE LISTING

<110> Lichter, Jay
Guido, Marco

<120> GENOTYPING OF HUMAN CYP3A4

<130> SEQ-12P

<150> 60/058,612

<151> 1997-09-10

<160> 58

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2759

<212> DNA

<213> H. sapiens

<220>

<221> CDS

<222> (70)...(1581)

<223> Human CYP3A4 cDNA reference sequence

<400> 1

```

gaattcccaa agagcaacac agagctgaaa ggaagactca gaggagagag ataagtaagg      60
aaagtagtg atg gct ctc atc cca gac ttg gcc atg gaa acc tgg ctt ctc      111
      Met Ala Leu Ile Pro Asp Leu Ala Met Glu Thr Trp Leu Leu
          1             5             10

ctg gct gtc agc ctg gtg ctc ctc tat cta tat gga acc cat tca cat      159
Leu Ala Val Ser Leu Val Leu Leu Tyr Leu Tyr Gly Thr His Ser His
  15             20             25             30

gga ctt ttt aag aag ctt gga att cca ggg ccc aca cct ctg cct ttt      207
Gly Leu Phe Lys Lys Leu Gly Ile Pro Gly Pro Thr Pro Leu Pro Phe
          35             40             45

ttg gga aat att ttg tcc tac cat aag ggc ttt tgt atg ttt gac atg      255
Leu Gly Asn Ile Leu Ser Tyr His Lys Gly Phe Cys Met Phe Asp Met
          50             55             60

gaa tgt cat aaa aag tat gga aaa gtg tgg ggc ttt tat gat ggt caa      303
Glu Cys His Lys Lys Tyr Gly Lys Val Trp Gly Phe Tyr Asp Gly Gln
          65             70             75

cag cct gtg ctg gct atc aca gat cct gac atg atc aaa aca gtg cta      351
Gln Pro Val Leu Ala Ile Thr Asp Pro Asp Met Ile Lys Thr Val Leu
          80             85             90

gtg aaa gaa tgt tat tct gtc ttc aca aac cgg agg cct ttt ggt cca      399
Val Lys Glu Cys Tyr Ser Val Phe Thr Asn Arg Arg Pro Phe Gly Pro
          95             100            105            110

gtg gga ttt atg aaa agt gcc atc tct ata gct gag gat gaa gaa tgg      447
Val Gly Phe Met Lys Ser Ala Ile Ser Ile Ala Glu Asp Glu Glu Trp
          115            120            125

aag aga tta cga tca ttg ctg tct cca acc ttc acc agt gga aaa ctc      495
Lys Arg Leu Arg Ser Leu Leu Ser Pro Thr Phe Thr Ser Gly Lys Leu
          130            135            140

```

aag gag atg gtc cct atc att gcc cag tat gga gat gtg ttg gtg aga Lys Glu Met Val Pro Ile Ile Ala Gln Tyr Gly Asp Val Leu Val Arg 145 150 155	543
aat ctg agg cgg gaa gca gag aca ggc aag cct gtc acc ttg aaa gac Asn Leu Arg Arg Glu Ala Glu Thr Gly Lys Pro Val Thr Leu Lys Asp 160 165 170	591
gtc ttt ggg gcc tac agc atg gat gtg atc act agc aca tca ttt gga Val Phe Gly Ala Tyr Ser Met Asp Val Ile Thr Ser Thr Ser Phe Gly 175 180 185 190	639
gtg aac atc gac tct ctc aac aat cca caa gac ccc ttt gtg gaa aac Val Asn Ile Asp Ser Leu Asn Asn Pro Gln Asp Pro Phe Val Glu Asn 195 200 205	687
acc aag aag ctt tta aga ttt gat ttt ttg gat cca ttc ttt ctc tca Thr Lys Lys Leu Leu Arg Phe Asp Phe Leu Asp Pro Phe Phe Leu Ser 210 215 220	735
ata aca gtc ttt cca ttc ctc atc cca att ctt gaa gta tta aat atc Ile Thr Val Phe Pro Phe Leu Ile Pro Ile Leu Glu Val Leu Asn Ile 225 230 235	783
tgt gtg ttt cca aga gaa gtt aca aat ttt tta aga aaa tct gta aaa Cys Val Phe Pro Arg Glu Val Thr Asn Phe Leu Arg Lys Ser Val Lys 240 245 250	831
agg atg aaa gaa agt cgc ctc gaa gat aca caa aag cac cga gtg gat Arg Met Lys Glu Ser Arg Leu Glu Asp Thr Gln Lys His Arg Val Asp 255 260 265 270	879
ttc ctt cag ctg atg att gac tct cag aat tca aaa gaa act gag tcc Phe Leu Gln Leu Met Ile Asp Ser Gln Asn Ser Lys Glu Thr Glu Ser 275 280 285	927
cac aaa gct ctg tcc gat ctg gag ctc gtg gcc caa tca att atc ttt His Lys Ala Leu Ser Asp Leu Glu Leu Val Ala Gln Ser Ile Ile Phe 290 295 300	975
att ttt gct ggc tat gaa acc acg agc agt gtt ctc tcc ttc att atg Ile Phe Ala Gly Tyr Glu Thr Thr Ser Ser Val Leu Ser Phe Ile Met 305 310 315	1023
tat gaa ctg gcc act cac cct gat gtc cag cag aaa ctg cag gag gaa Tyr Glu Leu Ala Thr His Pro Asp Val Gln Gln Lys Leu Gln Glu Glu 320 325 330	1071
att gat gca gtt tta ccc aat aag gca cca ccc acc tat gat act gtg Ile Asp Ala Val Leu Pro Asn Lys Ala Pro Pro Thr Tyr Asp Thr Val 335 340 345 350	1119
cta cag atg gag tat ctt gac atg gtg gtg aat gaa acg ctc aga tta Leu Gln Met Glu Tyr Leu Asp Met Val Val Asn Glu Thr Leu Arg Leu 355 360 365	1167
ttc cca att gct atg aga ctt gag agg gtc tgc aaa aaa gat gtt gag Phe Pro Ile Ala Met Arg Leu Glu Arg Val Cys Lys Lys Asp Val Glu 370 375 380	1215
atc aat ggg atg ttc att ccc aaa ggg tgg gtg gtg atg att cca agc Ile Asn Gly Met Phe Ile Pro Lys Gly Trp Val Val Met Ile Pro Ser 385 390 395	1263

tat gct ctt cac cgt gac cca aag tac tgg aca gag cct gag aag ttc 1311
Tyr Ala Leu His Arg Asp Pro Lys Tyr Trp Thr Glu Pro Glu Lys Phe
400 405 410

ctc cct gaa aga ttc agc aag aag aac aag gac aac ata gat cct tac 1359
Leu Pro Glu Arg Phe Ser Lys Lys Asn Lys Asp Asn Ile Asp Pro Tyr
415 420 425 430

ata tac aca ccc ttt gga agt gga ccc aga aac tgc att ggc atg agg 1407
Ile Tyr Thr Pro Phe Gly Ser Gly Pro Arg Asn Cys Ile Gly Met Arg
435 440 445

ttt gct ctc atg aac atg aaa ctt gct cta atc aga gtc ctt cag aac 1455
Phe Ala Leu Met Asn Met Lys Leu Ala Leu Ile Arg Val Leu Gln Asn
450 455 460

ttc tcc ttc aaa cct tgt aaa gaa aca cag atc ccc ctg aaa tta agc 1503
Phe Ser Phe Lys Pro Cys Lys Glu Thr Gln Ile Pro Leu Lys Leu Ser
465 470 475

tta gga gga ctt ctt caa cca gaa aaa ccc gtt gtt cta aag gtt gag 1551
Leu Gly Gly Leu Leu Gln Pro Glu Lys Pro Val Val Leu Lys Val Glu
480 485 490

tca agg gat ggc acc gta agt gga gcc tga attttcctaa ggacttctgc 1601
Ser Arg Asp Gly Thr Val Ser Gly Ala *

495 500

tttgctcttc aagaaatctg tgcttgagaa caccagagac ctcaaattac tttgtgaata 1661
gaactctgaa atgaagatgg gcttcatcca atggactgca taaataaccg gggattctgt 1721
acatgcattg agctctctca ttgtctgtgt agagtgttat acttgggaat ataaaggagg 1781
tgaccaaacc agtgtgagga ggtagatttg gtcctctctg ttctcacggg actattttcca 1841
ccacccccag ttagcaccat taactcctcc tgagctctga taagagaatc aacattttctc 1901
aataattttcc tccacaaatt attaatgaaa ataagaatta ttttgatggc tctaacaatg 1961
acattttatat cacatgtttt ctctggagta ttctatagtt ttatgttaaa tcaataaaga 2021
ccactttaca aaagtattat cagatgcttt cctgcacatt aaggagaatc tatagaactg 2081
aatgagaacc aacaagtaaa tatttttggg cattgtaatc actgttggcg tggggccttt 2141
gtcagaacta gaatttgatt attaacatag gtgaaagtta atccactgtg actttgcccc 2201
ttgttttagaa agaattattca tagtttaatt atgccttttt tgatcaggca catggctcac 2261
gcctgtaatc ctagcagttt gggaggctga gccgggtgga tgcctgagg tcaggagttc 2321
aagacaagcc tggcctacat ggtgaaaccc catctctact aaaaatacac aaattagcta 2381
ggcatggttg actgcctgt aatctcacta cacaggaggc tgaggcagga gaatcacttg 2441
aacctgggag gcggatgttg aagtgaactg agattgcacc actgcactcc agtctgggtg 2501
agagtgaag tcagctctta aaaaatatgc ctttttgaag cactgtacatt ttgtaacaaa 2561
gaactgaagc tcttattata ttattagttt tgatttaatg ttttcagccc atctcctttc 2621
atatttcttg gagacagaaa acatgtttcc ctacacctct tgcctccatc ctcaacaccc 2681
aactgtctcg atgcaatgaa cacttaataa aaaacagtcg attggtcaaa aaaaaaaaaa 2741
aaaaaaaaa aagaattc 2759

<210> 2
<211> 503
<212> PRT
<213> H. sapiens

<400> 2
Met Ala Leu Ile Pro Asp Leu Ala Met Glu Thr Trp Leu Leu Leu Ala
1 5 10 15
Val Ser Leu Val Leu Leu Tyr Leu Tyr Gly Thr His Ser His Gly Leu
20 25 30
Phe Lys Lys Leu Gly Ile Pro Gly Pro Thr Pro Leu Pro Phe Leu Gly
35 40 45
Asn Ile Leu Ser Tyr His Lys Gly Phe Cys Met Phe Asp Met Glu Cys
50 55 60
His Lys Lys Tyr Gly Lys Val Trp Gly Phe Tyr Asp Gly Gln Gln Pro
65 70 75 80

Val Leu Ala Ile Thr Asp Pro Asp Met Ile Lys Thr Val Leu Val Lys
 85 90 95
 Glu Cys Tyr Ser Val Phe Thr Asn Arg Arg Pro Phe Gly Pro Val Gly
 100 105 110
 Phe Met Lys Ser Ala Ile Ser Ile Ala Glu Asp Glu Glu Trp Lys Arg
 115 120 125
 Leu Arg Ser Leu Leu Ser Pro Thr Phe Thr Ser Gly Lys Leu Lys Glu
 130 135 140
 Met Val Pro Ile Ile Ala Gln Tyr Gly Asp Val Leu Val Arg Asn Leu
 145 150 155 160
 Arg Arg Glu Ala Glu Thr Gly Lys Pro Val Thr Leu Lys Asp Val Phe
 165 170 175
 Gly Ala Tyr Ser Met Asp Val Ile Thr Ser Thr Ser Phe Gly Val Asn
 180 185 190
 Ile Asp Ser Leu Asn Asn Pro Gln Asp Pro Phe Val Glu Asn Thr Lys
 195 200 205
 Lys Leu Leu Arg Phe Asp Phe Leu Asp Pro Phe Phe Leu Ser Ile Thr
 210 215 220
 Val Phe Pro Phe Leu Ile Pro Ile Leu Glu Val Leu Asn Ile Cys Val
 225 230 235 240
 Phe Pro Arg Glu Val Thr Asn Phe Leu Arg Lys Ser Val Lys Arg Met
 245 250 255
 Lys Glu Ser Arg Leu Glu Asp Thr Gln Lys His Arg Val Asp Phe Leu
 260 265 270
 Gln Leu Met Ile Asp Ser Gln Asn Ser Lys Glu Thr Glu Ser His Lys
 275 280 285
 Ala Leu Ser Asp Leu Glu Leu Val Ala Gln Ser Ile Ile Phe Ile Phe
 290 295 300
 Ala Gly Tyr Glu Thr Thr Ser Ser Val Leu Ser Phe Ile Met Tyr Glu
 305 310 315 320
 Leu Ala Thr His Pro Asp Val Gln Gln Lys Leu Gln Glu Glu Ile Asp
 325 330 335
 Ala Val Leu Pro Asn Lys Ala Pro Pro Thr Tyr Asp Thr Val Leu Gln
 340 345 350
 Met Glu Tyr Leu Asp Met Val Val Asn Glu Thr Leu Arg Leu Phe Pro
 355 360 365
 Ile Ala Met Arg Leu Glu Arg Val Cys Lys Lys Asp Val Glu Ile Asn
 370 375 380
 Gly Met Phe Ile Pro Lys Gly Trp Val Val Met Ile Pro Ser Tyr Ala
 385 390 395 400
 Leu His Arg Asp Pro Lys Tyr Trp Thr Glu Pro Glu Lys Phe Leu Pro
 405 410 415
 Glu Arg Phe Ser Lys Lys Asn Lys Asp Asn Ile Asp Pro Tyr Ile Tyr
 420 425 430
 Thr Pro Phe Gly Ser Gly Pro Arg Asn Cys Ile Gly Met Arg Phe Ala
 435 440 445
 Leu Met Asn Met Lys Leu Ala Leu Ile Arg Val Leu Gln Asn Phe Ser
 450 455 460
 Phe Lys Pro Cys Lys Glu Thr Gln Ile Pro Leu Lys Leu Ser Leu Gly
 465 470 475 480
 Gly Leu Leu Gln Pro Glu Lys Pro Val Val Leu Lys Val Glu Ser Arg
 485 490 495
 Asp Gly Thr Val Ser Gly Ala
 500

<210> 3
 <211> 1345
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (0)...(0)

<400> 3

ctgcagtgac	cactgcecca	tcattgctgg	ctgaggtggt	tggggtccat	ctgggtatct	60
gggcagctgt	tctcttctct	cctttctctc	ctgtttccag	acatgcagta	tttccagaga	120
gaaggggcca	ctctttggca	aagaacctgt	ctaacttgct	atctatggca	ggacctttga	180
aggggttcaca	ggaagcagca	caaattgata	ctattccacc	aagccatcag	ctccatctca	240
tccatgccct	gtctctcctt	taggggtccc	cttgccaaca	gaatcacaga	ggaccagcct	300
gaaagtgcag	agacagcagc	tgaggcacag	ccaagagctc	tggctgtatt	aatgacctaa	360
gaagtcacca	gaaagtcaga	aggatgcata	gcagaggccc	agcaatctca	gctaagtcaa	420
ctccaccagc	ctttctagtt	gcccactgtg	tgtacagcac	cctggtaggg	accagagcca	480
tgacagggaa	taagactaga	ctatgccctt	gaggagctca	cctctgttca	gggaaacagg	540
cgtggaaaca	caatggtggt	aaagaggaaa	gaggacaata	ggattgcatg	aaggggatgg	600
aaagtgccca	ggggaggaaa	tggttacatc	tgtgtgagga	gtttggtgag	gaaagactct	660
aagagaaggc	tctgtctgtc	tgggtttgga	aggatgtgta	ggagtcttct	agggggcaca	720
ggcacactcc	aggcataggt	aaagatctgt	agggtgtggc	tgttgggatg	aatttcaagt	780
attttgggaat	gaggacagcc	atagagacaa	gggcargaga	gaggcgattt	aatagatttt	840
atgccaatgg	ctccacttga	gtttctgata	agaaccacga	acccttggac	tccccagtaa	900
cattgattga	gttgtttatg	atacctcata	gaatatgaac	tcaaaggagg	tcaagtgaag	960
gtgtgtgtgt	gattctttgc	caacttccaa	ggtggagaag	cctcttccaa	ctgcaggcag	1020
agcacagggt	gccctgctac	tggctgcagc	tccagccctg	cctccttctc	tagcatataa	1080
acaatccaac	agcctcactg	aatcactgct	gtgcagggca	ggaaagctcc	atgcacatag	1140
cccagcaaag	agcaacacag	agctgaaagg	aagactcaga	ggagagagat	aagtaaggaa	1200
agtagtgatg	gctctcatcc	cagacttggc	catggaaacc	tggcttctcc	tggctgtcag	1260
cctggtgctc	ctctatctgt	gagtaactgt	tcaggctcct	cttctctgtt	tcttggactt	1320
ggggtcgtaa	tcaggcctct	ctttt				1345

<210> 4
 <211> 591
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (0)...(0)

ggctttttgta	tgtttgacat	ggaatgtcat	aaaaagtatg	gaaaagtgtg	ggggtgagta	60
ttctggaaac	ttccattgga	tagacttggt	tctatgatga	gtttacccca	ctgcacagag	120
gacagtctca	gccc aaagcc	tcttgggatg	aagctcttgt	caacctaaact	acaaacagag	180
agaagtcttc	tgaagaaga	agatatttat	ttgggtgtag	agtattgcaa	tgggaatctg	240
catgccttta	taaactatgt	gcaaattcag	ggaagttaaag	caagacaaag	aggctccaag	300
gaaaatatga	aggaggattt	cttatcagtt	ttgaaataat	tatccttcgc	tacaaagatc	360
agtaacaagg	gtgacgcctc	accaagggtt	gacaggcagt	tgctgggcag	gtgtccttgc	420
agaaatatatt	ttttaatggt	gggatggcct	ttgtgcaagc	ttgtattttg	cggagtcttt	480
gtgatatttt	gttatcaggc	acacaagcat	gagaatcctc	tcttcatagc	cttctttgat	540
ttattttgtca	gggtttttac	acacacacac	acacacacac	acacacacac	a	591

<210> 5
 <211> 433
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (0)...(0)

catcacccag	tagacagtca	ctaaatagtt	gttgaataag	tgttcctgtt	taacacattt	60
tctacaacca	tggagacctc	cacaactgat	gtaggacaaa	atgtttctgc	tttsaactct	120
agccttttgg	tccagtggga	tttatgaaaa	gtgccatctc	tatagctgag	gatgaagaat	180
ggaagagatt	acgatcattg	ctgtctccaa	ccttcaccag	tggaaaactc	aaggagggtat	240
gaaaataaca	tgagttttta	taagaaactt	aaagaatgaa	tctgggtggg	acagggtataa	300
aataagatca	cagtcctttt	ccaaggggta	gtccactgaa	tttgagctgc	ctaaaaatgg	360
tcttttatct	ttatgtacag	aaaacacatc	acaaaattca	ttataaaatg	tcacttactg	420
ctccatgctg	ggg					433

<210> 6

<211> 408
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (0)...(0)

<400> 6
 tctgcacatt taactatggg tgggtgttggt ttttgtgctt agatgggtccc tatcattgccc 60
 cagtatggag atgtgttggg gagaaatctg aggcgggaag cagagacagg caagcctgtc 120
 accttgaaag agtaagtaga agcgcagcca tgggggtctg agctgtcatg aaccctcca 180
 gckgcctgcc atggagctga tattcctgct gttgggttat tccagtgacc agacaaaagg 240
 agggctgtgg taatgcaact tcaatgggtc tccaagatg gggcagctcc gatgaggagg 300
 tggggcagct ggaggaaaag gatcttctcc cctgtgcaca ggggccaggg tttacatata 360
 cattaattg tcaccttggg tattctagaa gactaaatat atccttta 408

<210> 7
 <211> 429
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (0)...(0)

<400> 7
 ttttaatttt ccacatcttt ctccactcag cgtctttggg gcctacagca tggatgtgat 60
 cactagcaca tcatttggag tgaacatyga ctctctcaac aatccacaag accctttgt 120
 ggaaaacacc aagaagcttt taagatttga ttttttggat ccattctttc tctcaataag 180
 tatgtggact actatttctt tttatttata tktctctctt aaaaataact gctttattga 240
 gatataaatc accatgtaat tcatccactt aaaatataca gttcagtgat ttgtagtaca 300
 tttgaagata tgtgtgacca tcatcatttt aaactttaaa actttttttg tcaatctaga 360
 gacctcatal attttttagct atcagccccc tgtcacaaac cctgtcatca tatgcaacca 420
 ctaatcaac 429

<210> 8
 <211> 352
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (0)...(0)

<400> 8
 aattgctttt ctattctttt cccttaggga tttgagggtc tcacttagat ttctcttcat 60
 cttaaactgtg atgccttaca ttgatctgat ttacctaaaa tgtctttcct ctcttttcag 120
 ctctgtccga tctggagctc gtggcccaat caattatctt tatttttget ggctatgaaa 180
 ccacgagcag tgttctctcc ttcattatgt atgaactggc cactcaccct gatgtccagc 240
 agaaactgca ggaggaaatt gatgcagttt tacccaataa ggtgagtggg tgrtacatgg 300
 agaaggaggg aggaggtgaa accttagcaa aaatgcctcc tcaccacttc cc 352

<210> 9
 <211> 309
 <212> DNA
 <213> H. sapiens

<220>
 <221> Other
 <222> (0)...(0)

<400> 9
 gcatagcagg atttcaatga ccagcccaca aaagtatcct gtgtactact agttgagggg 60
 tggccctctaa gtaagaaacc ctaacatgta actcttaggg gtattatgtc attaatcttt 120

taaaaatcta ccaaygtgga accagattca gcaagaagaa caaggacaac atagatcctt	180
acatatacac acccttttga agtggaccca gaaactgcat tggcatgagg ttggtctca	240
tgaacatgaa acttgcctta atcagagtcc ttcagaactt ctccctcaaa ccttgtaaag	300
aaacacagg	309

<210> 10
 <211> 24
 <212> DNA
 <213> H. sapiens

<400> 10	
tggcttggtg ggatgaattt caag	24

<210> 11
 <211> 24
 <212> DNA
 <213> H. sapiens

<400> 11	
ttactgggga gtccaagggt tctg	24

<210> 12
 <211> 32
 <212> DNA
 <213> H. sapiens

<400> 12	
ttaaatgcc tctctcttgc ccttgcctct at	32

<210> 13
 <211> 29
 <212> DNA
 <213> H. sapiens

<400> 13	
aatgcctct ctccctgccct tgtctctat	29

<210> 14
 <211> 17
 <212> DNA
 <213> H. sapiens

<400> 14	
tgaggagttt ggtgagg	17

<210> 15
 <211> 18
 <212> DNA
 <213> H. sapiens

<400> 15	
caagaaacag agaagagg	18

<210> 16
 <211> 17
 <212> DNA
 <213> H. sapiens

<400> 16	
cccacacaaa tacatcc	17

<210> 17
 <211> 17
 <212> DNA
 <213> H. sapiens

<400> 17
agaagacatg gctttcc 17

<210> 18
<211> 17
<212> DNA
<213> H. sapiens

<400> 18
tgtcacttac tgctcca 17

<210> 19
<211> 16
<212> DNA
<213> H. sapiens

<400> 19
caacaggaaa cccaca 16

<210> 20
<211> 18
<212> DNA
<213> H. sapiens

<400> 20
tccacaatca atacatgc 18

<210> 21
<211> 15
<212> DNA
<213> H. sapiens

<400> 21
cctgaagcca gcaga 15

<210> 22
<211> 20
<212> DNA
<213> H. sapiens

<400> 22
catctcaaca agactgaaag 20

<210> 23
<211> 18
<212> DNA
<213> H. sapiens

<400> 23
tgaactccag aactgaag 18

<210> 24
<211> 18
<212> DNA
<213> H. sapiens

<400> 24
ggcttttgta tgtttgac 18

<210> 25
<211> 16
<212> DNA
<213> H. sapiens

<400> 25

cggtttgtga agacag 16
 <210> 26
 <211> 18
 <212> DNA
 <213> H. sapiens
 <400> 26
ccttgaggaa aactggat 18
 <210> 27
 <211> 16
 <212> DNA
 <213> H. sapiens
 <400> 27
ctcctgggaa gtggtg 16
 <210> 28
 <211> 17
 <212> DNA
 <213> H. sapiens
 <400> 28
tgaggagttt ggtgagg 17
 <210> 29
 <211> 18
 <212> DNA
 <213> H. sapiens
 <400> 29
caagaaacag agaagagg 18
 <210> 30
 <211> 18
 <212> DNA
 <213> H. sapiens
 <400> 30
gtgagtgggtg tgtgtgtg 18
 <210> 31
 <211> 18
 <212> DNA
 <213> H. sapiens
 <400> 31
gtgattcagt gaggctgt 18
 <210> 32
 <211> 21
 <212> DNA
 <213> H. sapiens
 <400> 32
gggataaatc tctattgagc a 21
 <210> 33
 <211> 17
 <212> DNA
 <213> H. sapiens
 <400> 33
gctttctca gcatgga 17

<210> 34
 <211> 17
 <212> DNA
 <213> H. sapiens

 <400> 34
 tgtcacttac tgctcca 17

 <210> 35
 <211> 17
 <212> DNA
 <213> H. sapiens

 <400> 35
 cacaggggag aagatcc 17

 <210> 36
 <211> 18
 <212> DNA
 <213> H. sapiens

 <400> 36
 tgtctgtctg gactggac 18

 <210> 37
 <211> 19
 <212> DNA
 <213> H. sapiens

 <400> 37
 aaaatgatga tggtcacac 19

 <210> 38
 <211> 21
 <212> DNA
 <213> H. sapiens

 <400> 38
 tagtgtcagg agagtagaaa g 21

 <210> 39
 <211> 18
 <212> DNA
 <213> H. sapiens

 <400> 39
 gcctaattga ttcttttg 18

 <210> 40
 <211> 18
 <212> DNA
 <213> H. sapiens

 <400> 40
 atttgccetta ttctggtt 18

 <210> 41
 <211> 16
 <212> DNA
 <213> H. sapiens

 <400> 41
 ctctctgggaa gtggtg 16

 <210> 42

<211> 18
<212> DNA
<213> H. sapiens

<400> 42
ggcttttgta tgtttgac 18

<210> 43
<211> 19
<212> DNA
<213> H. sapiens

<400> 43
acaagggcaa gagagaggc 19

<210> 44
<211> 19
<212> DNA
<213> H. sapiens

<400> 44
acaagggcag gagagaggc 19

<210> 45
<211> 9
<212> DNA
<213> H. sapiens

<400> 45
gggttttta 9

<210> 46
<211> 41
<212> DNA
<213> H. sapiens

<400> 46
gggtttttac acacacacac acacacacac acacacacac a 41

<210> 47
<211> 19
<212> DNA
<213> H. sapiens

<400> 47
ttctgctttg aactctagc 19

<210> 48
<211> 19
<212> DNA
<213> H. sapiens

<400> 48
ttctgctttc aactctagc 19

<210> 49
<211> 19
<212> DNA
<213> H. sapiens

<400> 49
ccctccagct gcctgccat 19

<210> 50
<211> 19

<212> DNA
<213> H. sapiens

<400> 50
ccctccagcg gcctgccat 19

<210> 51
<211> 19
<212> DNA
<213> H. sapiens

<400> 51
agtgaacatc gactctctc 19

<210> 52
<211> 19
<212> DNA
<213> H. sapiens

<400> 52
agtgaacatt gactctctc 19

<210> 53
<211> 19
<212> DNA
<213> H. sapiens

<400> 53
atttatcttt ctctcttaa 19

<210> 54
<211> 19
<212> DNA
<213> H. sapiens

<400> 54
atttatcttg ctctcttaa 19

<210> 55
<211> 19
<212> DNA
<213> H. sapiens

<400> 55
gagtggatgg tacatggag 19

<210> 56
<211> 19
<212> DNA
<213> H. sapiens

<400> 56
gagtggatga tacatggag 19

<210> 57
<211> 18
<212> DNA
<213> H. sapiens

<400> 57
tctaccaacg tggaacca 18

<210> 58
<211> 18
<212> DNA

WO 99/13106

PCT/US98/18158

<213> H. sapiens

<400> 58

tctaccaatg tggaacca

18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/18158

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68; C12P 19/34; C07H 21/04; G01N 33/00

US CL : 435/6, 91.1; 536/23.5, 24.31; 436/94

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 69.1, 91.1, 91.2, 183; 536/23.5, 24.31; 436/94

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	LEWIS et al. Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. TOXICOLOGY. 29 September 1998, Volume 125, pages 31-44, see entire document.	1-12
Y	US 5,478,723 A (PARKINSON et al.) 26 December 1995, see column 5 and columns 8-11.	1-12
Y	US 5,506,131 A (HARRIS et al.) 09 April 1996, see columns 3-9.	1-12
Y	US 5,660,986 A (HARRIS et al.) 26 August 1997, see columns 3-9.	1-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* *A* *B* *L* *O* *P*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	*T* *X* *Y* *Z*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	---	--------------------------	--

Date of the actual completion of the international search

29 SEPTEMBER 1998

Date of mailing of the international search report

29 OCT 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRADLEY L. SISSON

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/18158

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,420,027 A (FISHER et al.) 30 May 1995, see entire document and especially column 23.	1-3
--		-----
Y		4-12

Form PCT/ISA/210 (continuation of second sheet)(July 1992)★

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/18158

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS (Files- USPAT, EPO, JPO); STN (Files- BIOSIS, MEDLINE)

Search terms: CYP3A4; CYP3A7; cytochrome p450; polymorphism; liver; e guida, marco/au;